Trial
NCT02992860
Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED THERAPY
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
GWT-TUD GmbH
Collaborators
—
Condition
Myelodysplastic Syndrome (MDS)
Intervention
JNJ-56022473
Why stopped
Enrollement was stopped due to a recommendation by the IDMC/FDA for a parallel clinical trial with TALA, where potentielly no efficancy could be determined.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-10-25